Skip to main content

Table 4 Kendall association coefficients between WPS and clinical and HRQoL assessments at baseline (randomized set, observed cases)

From: Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis

  WPS question
  2: number of work days missed because of arthritis 3: number of days with work productivity reduced by one-half or more because of arthritis 4: rate of arthritis interference with work productivity on a scale of 0 to 10 5: number of days with no household work because of arthritis 6: number of days with household work productivity reduced by one-half or more because of arthritis 7: number of days missed of family, social, or leisure activities because of arthritis 8: number of days with outside help hired because of arthritis 9: rate of arthritis interference with household work productivity on a scale of 0 to 10
DAS28 (CRP) 0.16** 0.09 0.16** 0.22** 0.13** 0.15** 0.12* 0.24**
PASIa 0.11 0.06 −0.02 −0.01 0.05 0 0.02 −0.04
HAQ-DI 0.25** 0.21** 0.32** 0.34** 0.26** 0.28** 0.22** 0.38**
SF-36 MCS −0.16** −0.16** −0.22** −0.23** −0.24** −0.34** −0.24** −0.28**
SF-36 PCS −0.19** −0.15** −0.28** −0.31** −0.20** −0.19** −0.15** −0.32**
SF-36 PF −0.22** −0.16** −0.27** −0.36** −0.22** −0.25** −0.20** −0.34**
SF-36 BP −0.29** −0.20** −0.33** −0.34** −0.24** −0.33** −0.19** −0.38**
SF-36 RE −0.24** −0.21** −0.28** −0.29** −0.23** −0.35** −0.30** −0.31**
SF-36 RP −0.26** −0.24** −0.34** −0.32** −0.26** −0.28** −0.23** −0.37**
SF-36 GH −0.07 −0.09 −0.18** −0.16** −0.15** −0.15** −0.17** −0.20**
SF-36 MH −0.15* −0.15* −0.20** −0.19** −0.23** −0.29** −0.21** −0.27**
SF-36 SF −0.17** −0.21** −0.26** −0.30** −0.26** −0.36** −0.17** −0.30**
SF-36 VT −0.14* −0.10* −0.18** −0.27** −0.22** −0.27** −0.17** −0.30**
PsAQoL 0.24** 0.23** 0.30** 0.28** 0.28** 0.37** 0.27** 0.35**
DLQI 0.11 # 0.03 0.06 0.08# 0.09* 0.15** 0.08# 0.10*
EQ-5D VAS −0.09 −0.09 −0.19** −0.15** −0.13** −0.14** −0.12** −0.20**
  1. aAssessed only in patients with at least 3% body surface area at baseline. **P ≤ 0.001. *P ≤ 0.01. #P ≤ 0.05.
  2. WPS Questions 2 to 4 were assessed in employed patients only, whereas Questions 5 to 9 were assessed in all patients; Questions 4 and 9 are 0 to 10 scales, where 0 = no interference and 10 = complete interference. Correlation level (absolute value): low correlations, 0 to 0.1 (plain text), 0.1 (inclusive) to 0.3 (italic); moderate correlation, ≥0.3 to <0.5 (bold). HAQ-DI, lower score = better; DAS28, lower score = better; PASI, lower score = better; PsAQoL, lower score = better; DLQI, lower score = better; SF-36, higher score = better; EQ-5D VAS, higher score = better. BP, bodily pain; DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive protein; DLQI, Dermatology Life Quality Index; DMARD, disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5 dimensions; GH, general health; HAQ-DI, Health Assessment Questionnaire – Disability Index; HRQoL, health-related quality of life; MCS, mental component summary; MH, mental health; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-36, Short Form-36 items; VAS, visual analogue scale; VT, vitality; WPS, Work Productivity Survey.